Adar1 Capital Management, LLC Portfolio Holdings

Adar1 Capital Management, LLC

  • $500 Billion
  • Q4 2024

Adar1 Capital Management, LLC has filed its 13F form on February 13, 2025 for Q4 2024 where it was disclosed a total value porftolio of $500 Billion distributed in 214 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Roivant Sciences Ltd. with a value of $41.5B, Protagonist Therapeutics, Inc with a value of $39.4B, Ea Series Trust with a value of $35.9B, Zai Lab LTD with a value of $27.4B, and Immunovant, Inc. with a value of $19.5B.

Examining the 13F form we can see an decrease of $115B in the current position value, from $615B to 500B.

Adar1 Capital Management, LLC is based out at Austin, TX

Below you can find more details about Adar1 Capital Management, LLC portfolio as well as his latest detailed transactions.

Portfolio value $500 Billion
Healthcare: $303 Billion
ETFs: $17.1 Billion
Communication Services: $6.59 Billion
Utilities: $178 Million
Energy: $111 Million
Financial Services: $588,000

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$3.69B
$600 Million 0.12% of portfolio
40,200
Q4 2024 Added 1,196.77%
$23.5B
$549 Million 0.11% of portfolio
2,974
Q4 2024 Added 204.09%
$1.24B
$485 Million 0.1% of portfolio
25,147
Q4 2024 New
$576M
$498 Million 0.1% of portfolio
26,000
Q4 2024 Added 182.42%
$2.67B
$479 Million 0.1% of portfolio
15,000
Q4 2024 Reduced 13.05%
$0
$503 Million 0.1% of portfolio
10,000
Q3 2024 Reduced 81.13%
$259M
$450 Million 0.09% of portfolio
55,400
Q4 2024 Added 27,600.0%
$745M
$425 Million 0.09% of portfolio
122,236
Q4 2024 Reduced 49.19%
Nabors Energy Transition Cor
-
$431 Million 0.09% of portfolio
-
Q4 2024 Reduced 33.39%
$1.98B
$426 Million 0.09% of portfolio
15,307
Q4 2024 Reduced 33.47%
$19.9B
$466 Million 0.09% of portfolio
3,045
Q4 2024 Reduced 89.72%
$889M
$470 Million 0.09% of portfolio
64,067
Q4 2024 Reduced 79.93%
Dianthus Therapeutics Inc
-
$385 Million 0.08% of portfolio
-
Q4 2024 Reduced 85.11%
$1.62B
$402 Million 0.08% of portfolio
10,000
Q4 2024 Reduced 15.65%
$251M
$413 Million 0.08% of portfolio
157,665
Q4 2024 Reduced 84.32%
Vistagen Therapeutics Inc
-
$358 Million 0.07% of portfolio
-
Q4 2024 Reduced 25.52%
$2.65B
$337 Million 0.07% of portfolio
8,000
Q4 2024 New
Anaptysbio Inc
-
$361 Million 0.07% of portfolio
-
Q4 2024 Reduced 85.83%
$278M
$368 Million 0.07% of portfolio
23,246
Q4 2024 Reduced 94.78%
$244M
$369 Million 0.07% of portfolio
110,000
Q4 2024 New
$10.5M
$369 Million 0.07% of portfolio
351,094
Q4 2024 Reduced 6.08%
$1.97B
$374 Million 0.07% of portfolio
9,300
Q4 2024 Added 30.99%
Leap Therapeutics Inc
-
$305 Million 0.06% of portfolio
-
Q4 2024 New
Jvspac Acquisition Corp
-
$313 Million 0.06% of portfolio
-
Q3 2024 New
$7.73B
$281 Million 0.06% of portfolio
5,000
Q4 2024 Reduced 67.11%
$294M
$304 Million 0.06% of portfolio
35,843
Q4 2024 Added 153.43%
$5.45B
$293 Million 0.06% of portfolio
10,188
Q4 2024 Reduced 86.31%
$88M
$307 Million 0.06% of portfolio
177,707
Q4 2024 Reduced 29.31%
$2.98B
$304 Million 0.06% of portfolio
3,962
Q3 2024 Added 3,862.0%
$110M
$267 Million 0.05% of portfolio
295,613
Q4 2024 Reduced 29.1%
$748M
$268 Million 0.05% of portfolio
21,700
Q4 2024 New
Polypid LTD
-
$243 Million 0.05% of portfolio
-
Q4 2024 Reduced 14.72%
$68.4M
$273 Million 0.05% of portfolio
124,530
Q4 2024 Added 27.13%
Iron Horse Acquisitions Corp
-
$257 Million 0.05% of portfolio
-
Q3 2024 New
$151M
$236 Million 0.05% of portfolio
23,700
Q4 2024 New
Therapeuticsmd Inc
-
$232 Million 0.05% of portfolio
-
Q2 2024 Reduced 0.73%
$9.07M
$254 Million 0.05% of portfolio
197,250
Q4 2024 Reduced 37.42%
$1.46B
$243 Million 0.05% of portfolio
12,900
Q4 2024 Added 10.21%
Disc Medicine Inc
-
$266 Million 0.05% of portfolio
-
Q4 2024 Reduced 81.4%
$2.37B
$273 Million 0.05% of portfolio
20,600
Q4 2024 New
$70.5M
$267 Million 0.05% of portfolio
142,958
Q3 2024 Added 53.79%
$1.46B
$263 Million 0.05% of portfolio
35,000
Q3 2024 Added 19.05%
$226B
$243 Million 0.05% of portfolio
2,440
Q4 2024 Added 114.04%
$254M
$192 Million 0.04% of portfolio
28,221
Q4 2024 New
Ginkgo Bioworks Holdings Inc
-
$183 Million 0.04% of portfolio
-
Q4 2024 New
$3.52B
$178 Million 0.04% of portfolio
40,000
Q4 2024 Reduced 50.0%
$36.9M
$211 Million 0.04% of portfolio
76,299
Q4 2024 New
Tenax Therapeutics Inc
-
$215 Million 0.04% of portfolio
-
Q4 2024 Reduced 44.42%
$573M
$207 Million 0.04% of portfolio
11,000
Q4 2024 New

Summary

  • Portfolio
  • No. of Stocks 214
  • Current Value $500 Billion
  • Prior Value $615 Billion
  • Filing
  • Period Q4 2024
  • Filing Date February 13, 2025
  • Form Type 13F-HR
  • Activity in Q4 2024
  • New Purchases 46 stocks
  • Additional Purchases 54 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 66 stocks
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email